An Open-Label, Dose-Escalation Safety and Tolerability Trial Assessing Multiple Dose Administrations of Anti-KIR (1-7F9) Human Monoclonal Antibody in Subjects With Multiple Myeloma.

Trial Profile

An Open-Label, Dose-Escalation Safety and Tolerability Trial Assessing Multiple Dose Administrations of Anti-KIR (1-7F9) Human Monoclonal Antibody in Subjects With Multiple Myeloma.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Dec 2012

At a glance

  • Drugs Lirilumab (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Dec 2012 Results have been published in Blood according to an Innate Pharma media release. Results were also briefly summarised in the media release.
    • 27 Jun 2012 Additional lead trial investigators identified as reported by ClinicalTrials.gov.
    • 07 Jun 2011 Actual end date (Jan 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top